Pulmatrix Inc (NASDAQ:PULM) Short Interest Down 5.8% in June

Share on StockTwits

Pulmatrix Inc (NASDAQ:PULM) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totalling 658,900 shares, a decline of 5.8% from the May 30th total of 699,100 shares. Based on an average daily trading volume, of 622,200 shares, the short-interest ratio is currently 1.1 days. Approximately 8.6% of the shares of the company are sold short.

NASDAQ PULM opened at $0.89 on Monday. The business has a 50 day simple moving average of $0.97. Pulmatrix has a 12 month low of $0.72 and a 12 month high of $5.90. The stock has a market cap of $16.28 million, a PE ratio of -0.18 and a beta of 1.33.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.01). As a group, equities analysts predict that Pulmatrix will post -1.9 EPS for the current year.

A number of research firms have recently weighed in on PULM. Zacks Investment Research cut Zurich Insurance Group from a “hold” rating to a “sell” rating in a research report on Saturday, April 20th. HC Wainwright reissued a “buy” rating on shares of Pulmatrix in a report on Tuesday, April 16th.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Read More: What is a Futures Contract?

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.